Description
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, as well as developments in diagnostic procedures and improvements in therapy and prevention. These therapies make it possible to eliminate hepatitis C as a major public health threat, as per the World Health Organization target, although the timeline and feasibility vary from region to region.
The EASL Recommendations on Treatment of Hepatitis C Webinar is intended to assist physicians and other healthcare providers, in the clinical decision-making process, by describing the current optimal management of patients with acute and chronic HCV infections.
Access the 2020 EASL Recommendations on Treatment of Hepatitis C slide deck.
Why attend
Live Webinar Faculty
- Thomas Berg, University of Leipzig, Leipzig, Germany
- Jean-Michel Pawlotsky, University of Paris-Est, Paris, France
- Marina Berenguer, La Fe University and Polytechnic Hospital, Valencia, Spain
- Geoffrey Dusheiko, University College London School of Medicine, London, United-Kingdom
Panel Members
- Francesco Negro, University Hospital of Geneva, Geneva, Switzerland
- Fiona Marra, University of Liverpool, Liverpool, United-Kingdom
- Olav Dalgard, Akershus University Hospital, Lørenskog, Norway
- Heiner Wedemeyer, The Hannover Medical School, Hannover, Germany
- Alessio Aghemo, Humanitas Research Hospital, Milan, Italy
- Massimo Puoti, The Ospedale Maggiore Policlinico of Milan, Milan, Italy
Programme
| Time | Title |
| 18:00-18:15 | Presentation of the new EASL Recommendations
Jean-Michel Pawlotsky |
| 18:15-18:20 | Extra-hepatic manifestations
Francesco Negro |
| 18:20-18:25 | Children and pregnant women
Fiona Marra |
| 18:25-18:30 | PWID and prisoners
Olav Dalgard |
| 18:30-18:35 | Organ (including liver) transplant setting
Marina Berenguer |
| 18:35-18:40 | Hepatocellular carcinoma
Geoffrey Dusheiko |
| 18:40-18:45 | Recently acquired hepatitis C
Heiner Wedemeyer |
| 18:45-18:50 | Treatment failures and retreatment
Alessio Aghemo |
| 18:50-18:55 | Reinfections
Massimo Puoti |
| 18:55-19:30 | Q&A session
Marina Berenguer Geoffrey Dusheiko Jean-Michel Pawlotsky Thomas Berg |
Target audience
- Hepatologists
- Health care professionals
- General HCV-treatment practitioners
Learning objectives
- Understand how to treat HCV infection in 2021 and beyond
- Learn how to use simplified HCV therapy to improve access to care
- Learn about new recommendations on special groups and comorbidities
- Understand how to handle patients with DAA treatment failures
- Apprehend how to implement simple treatment rules to achieve HCV elimination goals
